John Wood Group FY22 Adj. EBITDA From Cont. Ops. Flat On Last Year At Constant Currency

John Wood Group (WDGJF.PK,WG.L) posted a loss before tax from continuing operations of $694.5 million compared to a loss of $172.0 million, last year. Loss per share from continuing operations, in cents, was 104.4 compared a loss of 32.2. Adjusted EBITDA from continuing operations was $385 million, flat on last year at constant currency. Adjusted earnings per share, in cents, was 5.7 compared to 17.5.

Revenue was $5.4 billion, 8% higher at constant currency. The Group said this reflects good growth in Consulting and Operations and an improving trend in Projects, with a return to growth in the second half.

Looking forward, John Wood Group said its expectations for 2023 remain unchanged. The Group expects performance in fiscal 2023 to be line with medium-term targets.

The Group stated that no decision has been taken to resume the dividend and this will be kept under review by the directors.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT